Market context
Follow the story. See which markets it affects. Explore the context.
Harbor Mid Cap Value Fund trimmed its position in Cummins Inc. during Q2 2026 due to valuation deterioration relative to earnings. The letter highlighted strong broader market performance, with the S…
WestEnd Capital released its Q2 2026 investor letter, noting strong U.S. corporate earnings efficiency with S&P 500 net profit margins reaching decade-high levels of 14.8%. The fund also highlighted …
Madison Investments warned of extreme market narrowness driving S&P 500 gains amid AI hype. The fund added Intercontinental Exchange, arguing market concerns over AI disruption are misplaced while hi…
TCW's Q2 2026 letter reviews market gains driven by AI capex and earnings, but flags Boston Scientific's underperformance due to weak Watchman/EP results and lowered 2026 guidance despite positive CH…
Sands Capital's tech fund gained 26.9% in Q2 2026 on AI infrastructure strength, though concentrated mega-cap chip exposure lagged as gains broadened into CPUs, networking, and memory. New holding Ce…
Jensen Investment Management's Q2 2026 letter reviews fund performance versus S&P 500, highlighting TJX Companies as a top pick due to its scale, margin growth, and defensive earnings in off-price re…
Fund letter reviews Q2 2026 market recovery, S&P 500 up 15.2% on Iran ceasefire and AI optimism. Highlights small-cap infrastructure stock CDNL as top contributor, not a widely-traded symbol.
Fred Alger's Q2 2026 letter reviews a strong S&P 500 rally (+15.2%) driven by AI optimism and Iran ceasefire, while highlighting Forte Biosciences (FBRX) as a fund detractor due to equity raise conce…
Alger's Q2 2026 letter notes S&P 500 surged 15.2% amid US-Iran ceasefire and AI optimism; highlights Forte Biosciences (FBRX) as a fund detractor despite promising FB102 autoimmune drug data.